- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02745327
Nutrition, Overgrowth, and Vaccine Efficacy in Low-income Settings (NOVEL)
May 13, 2019 updated by: William Petri, MD, University of Virginia
A Longitudinal Study of Childhood Intestinal Bacterial Overgrowth, Vaccine Underperformance, and Malnutrition
The purpose of this study is to assess the impact of small intestine bacterial overgrowth (SIBO) on childhood nutritional status, growth, and oral vaccine efficacy.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
270
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dhaka, Bangladesh
- The International Centre for Diarrhoeal Disease Research, Bangladesh
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 1 week (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Bangladeshi infants from the low-income neighborhood of Mirpur, Dhaka
Description
Inclusion Criteria:
- Child previously enrolled in the FIELD STUDIES protocol (enrollments in both studies may occur simultaneously)
- Mother willing to sign informed consent form.
- Healthy infant aged less than 7 days old
Exclusion Criteria:
- Parents are not willing to have child's blood drawn, oral fluid collected, urine collected, or breath testing performed.
- History of seizures, other apparent neurologic disorders, or other congenital abnormalities involving major organ systems.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose-Hydrogen Breath Test
Time Frame: Birth to 2 years
|
Test for Small Intestine Bacterial Overgrowth
|
Birth to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Fecal Regenerating Islet-Derived 1 Beta (Reg 1B)
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Fecal Myeloperoxidase
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Serum 25-OH vitamin D
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Serum Zinc
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Serum Retinol Binding Protein
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Serum Cobalamin
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Serum Albumin
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Lactulose mannitol ratio
Time Frame: 12 weeks of age
|
12 weeks of age
|
Serum Tetanus antibody titers
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Serum Polio antibody titers to sabin strains
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Oral fluid Tetanus antibody titers
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Height
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Weight
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Head circumference
Time Frame: Birth to 2 years
|
Birth to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: William A Petri, M.D., PhD, University of Virginia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
December 1, 2018
Study Completion (Actual)
December 1, 2018
Study Registration Dates
First Submitted
April 15, 2016
First Submitted That Met QC Criteria
April 19, 2016
First Posted (Estimate)
April 20, 2016
Study Record Updates
Last Update Posted (Actual)
May 15, 2019
Last Update Submitted That Met QC Criteria
May 13, 2019
Last Verified
May 1, 2019
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PR14083
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Small Intestine Bacterial Overgrowth
-
Augusta UniversityCompletedColectomy | Small Intestinal Bacterial Overgrowth | Small Intestinal Fungal Overgrowth
-
Envivo Bio IncRecruitingSmall Intestinal Bacterial OvergrowthUnited States
-
McMaster Children's HospitalThe Hospital for Sick ChildrenRecruitingSmall Intestinal Bacterial OvergrowthCanada
-
The Functional Gut ClinicCompletedSmall Intestinal Bacterial OvergrowthUnited Kingdom
-
Atrium InnovationsGenova Diagnostics; Dr. Nathan Morris, MDWithdrawnSmall Intestinal Bacterial OvergrowthUnited States
-
San Antonio Military Medical CenterUnknownSmall Intestinal Bacterial Overgrowth
-
Augusta UniversityUnknownSmall Intestinal Bacterial OvergrowthUnited States
-
Integrative Skin Science and ResearchBiocidinRecruitingSmall Intestinal Bacterial Overgrowth (SIBO)United States
-
Shanghai 10th People's HospitalCompletedSmall Intestinal Bacterial Overgrowth | Fecal Microbiota TransplantationChina
-
Chinese PLA General HospitalUnknownElderly | Small Intestinal Bacterial Overgrowth | Male | 16s rRNAChina